Trial abstract · §3

ATTAIN-1 — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier: CEI-TR-0045/3
Series: Trial abstract
Version: 1.1
Published: 21 Jan 2025
Last reviewed: 21 Feb 2026
Next review: 21 Feb 2028
Identifier: 10.71829/cei.trial.45
Certainty: Moderate
Cycle: 2025 Q1
Phase: Phase 3
Status: Reported

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

Endpoint	Result as reported	Certainty
Percentage change in body weight from baseline to week 72	The Institute holds a headline result indicating a weight effect intermediate between the injectable single agonists and placebo, and awaits the full publication before reproducing a point estimate	Moderate
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

Figure 1. Illustrative. Categorical responder proportions derived by the Institute from the reported mean change under a logistic response model. These are not the published responder proportions for this trial. The figure is published because a mean conceals the distribution of response, and the shape of that distribution is what a reader most often wants and least often gets.

§3.3Harms as reported

Table 5. Adverse events for Orforglipron from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

Event	Active, %	Comparator, %	Source trial
Nausea	44.0	9.0	Phase 2 obesity (45 mg)
Vomiting	25.0	2.0	Phase 2 obesity
Constipation	21.0	9.0	Phase 2 obesity
Diarrhoea	24.0	12.0	Phase 2 obesity
Discontinuation for adverse events	10.0	2.0	Phase 2 obesity
Hepatic enzyme elevation	—	—	Monitored; no consistent signal reported in phase 2

Compound Evidence Institute · CEI-TR-0045/3 · https://compoundevidence.com/trials/attain-1/results/ · retrieved 30 July 2026